Sentences with phrase «for allogeneic»

Should all patients with Hodgkin lymphoma who relapse after autologous SCT be considered for allogeneic SCT?

In the future, outpatient blood and bone marrow stem cell transplantation will be offered to a broader group of patients with other blood disorders and for allogeneic transplants (transplant from non-twin donor stem cells).

Most multiple myeloma patients, however, are ineligible for allogeneic transplantation due to age and medical restrictions.

«It thus appears quite possible that these selective agonists will be administered in the future to patients who are candidates for allogeneic stem cell transplants.

Not exact matches

The company's lead product candidate, dilanubicel (NLA101), is currently being evaluated in two ongoing Phase 2 clinical trials in adult and pediatric patients with hematologic malignancies undergoing an allogeneic transplant and adult patients receiving high dose chemotherapy for Acute Myeloid Leukemia.

The subindication for which now data were available for the first time was allogeneic SCT with related donor in comparison with allogeneic SCT with unrelated donor.

That's exciting because it provides strong evidence that this miR may be a good target for controlling cGVHD after allogeneic BMT.»

HSCT is effectively used today as a form of «replacement» therapy for patients with hard - to - treat blood cancers, providing healthy cells from either the patient (autologous transplantation) or from a donor (allogeneic transplantation) to better equip patients to fight the disease on their own.

In the study, analysis of patient samples demonstrated that high LSC17 scores meant poor outcomes with current standard treatment, even for patients who had undergone allogeneic stem cell transplantation.

Of these 34 patients, 13 (38 %) have remained in remission for five years, and an additional two patients whose disease did not progress after BV went on to achieve remission after receiving allogeneic stem cell transplant (in which healthy stem cells are taken from a donor and administered to the patient).

Collaboration with Hematology and Bone Marrow Transplantation Unit research group in molecular diagnostics applied to the management of patients undergoing allogeneic SCT, especially for the detection of minimal residual disease and early relapse.

Granulocyte macrophage colony - stimulating factor — secreting allogeneic cellular immunotherapy for hormone - refractory prostate cancer.

As a result, they are currently being investigated as a cellular therapeutic for the treatment of autoimmune diseases and long - term patient and graft survival following solid organ transplantation, and allogeneic hematopoietic stem cell transplantation.

Sioud M, Mobergslien A, Boudabous A, Fløisand Y. Evidence for the involvement of galectin - 3 in mesenchymal stem cell suppression of allogeneic T - cell proliferation.

Mehta J, Gordon LI, Tallman MS, et al., Does younger donor age affect the outcome of reduced - intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?

There is supporting evidence for the use of allogeneic MSC from both in vitro and in vivo studies that show MSC avoid normal allo - responses.

Allogeneic Sibling Donor Peripheral Blood Stem Cells Transplantation With Myeloablative Conditioning for Chronic Myeloid Leukemia in Blast Crisis - Successful Treatment Despite Severe Phase of the Disease

In close collaboration with universities and physicians world - wide, our comprehensive investigational stem cell treatments employ well - targeted combinations of allogeneic human umbilical cord stem cells, autologous bone marrow stem cells, and autologous adipose stem cells for the diseases listed below.

We are planning to develop a product that would be an allogeneic, or donor - derived product, that could be used for similar indications in children and babies who don't have their own cell store.

Medipost (KOSDAQ: 078160, S. Korea) Two weeks ago, Medipost got a market approval for the first allogeneic stem cell drug — Cartistem.

Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS - IH).

Evidence from these studies indicates that the use of mismatched MSC does not provoke a proliferative T cell response in allogeneic MLR, thus suggesting an immunosuppressive role for MSC 83, 84, 85, 86, 87, 88.

For instance, during emergency care, allogeneic therapy is usually the only relevant option due to the time constraints of autologous cell expansion.

They hardly ever get mentioned on your blog, yet they might be the very first company in the world to actually commercialize allogeneic adipose - derived MSCs for «serious» indications!

Allogeneic Mesenchymal Stem Cells Stimulate Cartilage Regeneration and Are Safe for Single - Stage Cartilage Repair in Humans upon Mixture with Recycled Autologous Chondrons.

Hutter G and Thiel E Allogeneic transplantation of CCR5 - deficient progenitor cells in a patient with HIV infection: an update after 3 years and the search for patient no. 2.

Allogeneic cell therapies involving primary cell types such as bone marrow mesenchymal stromal / stem cells (BM - MSCs), hematopoietic stem and progenitor cells (HSPCs), and T and natural killer (NK) cells for immunotherapy applications are especially challenging because of the vigorous process of screening...

Warren D. Shlomchik, M.D. Yale University Memory T cells for improved immune reconstitution and GVL in allogeneic hematopoietic stem cell transplantation

• Patients must have adequate coagulation (international normalized ratio (INR) or prothrombin time (PT), partial thromboplastin time (PTT) ≤ 1.5 times ULN) • Adequate liver function (total bilirubin ≤ 1.5 times the ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN Exclusion Criteria: • Presence of active / uncontrolled central nervous system involvement • History of clinically significant cardiac disease; uncontrolled hypertension • Left ventricular ejection fraction (LVEF) < 45 % • Allogeneic stem cell transplant within 100 days before first dose of study drug • Known history of human immunodeficiency virus (HIV) infection • Chronic or active hepatitis B or C, requiring antiviral therapy • Evidence of history of bleeding disorder, dialysis, or coexisting cancer that is distinct in primary site or histology from the cancer evaluated in this study • Serious, uncontrolled infection • Unresolved chronic toxicity > grade 1 from prior therapy • Use of strong CYP3A4 inhibitors or strong inducers within 7 days prior to the start of study treatment and for the duration of the study

Low - dose donor CD8 + cells in the CD4 - depleted graft prevent allogeneic marrow graft rejection and severe graft - versus - host disease for chronic myeloid leukemia patients in first chronic phase.

Here we controlled for some of the features that differed among the earlier studies, and analyzed both the survival and expansion of naive CD4 + T cells transferred into MHC syngeneic, allogeneic, or MHC negative environments.

(A and B) Flow cytometry analysis of intracellular IFN - γ and IL - 17A on donor - derived CD4 + T cells from spleen on indicated days for syngeneic and allogeneic mice.

Although regulatory precedents have been set for various autologous and allogeneic products in the United States, Asia, and the European Union, regulatory guidance continues to evolve for a widening array of cell products.

Another possible complication for patients receiving allogeneic transplantation is known as graft - versus - host disease (GVHD).

Knowledge gained from mechanistic studies may contribute to the design of allogeneic vaccine - based or adoptive immunotherapy for breast cancer.

Allogeneic cells, particularly mismatched or haploidentical cells, in the context of hematopoietic transplantation have been found to provide potent immune surveillance for both hematologic and solid tumor malignancies in a process referred to as graft - versus - tumor [13]--[15].

One possible role of FMc in healthy women might be the provision of allogeneic immune surveillance for (pre --RRB- malignant cells.

Allogeneic cell therapies from primary cells for immunotherapy applications are especially challenging because of the vigor with which tissue donors must be screened and qualified to prevent transmission of infectious disease and ensure maintenance of an active donor pool.

These allogeneic cells have the potential to participate in immune surveillance for breast or other cancers as observed in clinical hematopoietic stem cell transplantation.

If these results are confirmed and one or more of these FLT3 - targeted drugs become approved by the FDA, testing for the FLT3 biomarker may eliminate the need for thousands of patients to undergo stem cell transplantation (each allogeneic transplant costs hundreds of thousands of dollars and place recipients at grave risk of infection and other complications such as Graft vs. Host disease).

He established the Long Term Transplant Clinic at Vanderbilt in 2006, which allows for systematic multidisciplinary follow up of patients after allogeneic stem cell transplant.

Thus, one can transplant fully allogeneic hematopoietic stem cells and co-transplant, for example, hearts from the hematopoietic stem cell donor to induce lifelong donor - specific acceptance of the transplant, without deleterious immunosuppression [4].

By integrating the aforementioned observations of FMc in autoimmunity and transplantation immunobiology, we reasoned that allogeneic FMc might provide immune surveillance for breast cancer in parous women.

Acute myeloid leukemia (AML) is the leading cause of leukemia mortality in the United States.1 Curative treatment involves intensive induction chemotherapy, before proceeding to either consolidation chemotherapy or allogeneic stem cell transplantation based on the patient's risk for relapse.2 This approach has been employed for > 4 decades and, although most individuals achieve complete remissions with front - line therapy, 3 the majority of patients ultimately relapse with drug - resistant disease, and overall survival rates remain disappointingly poor.4 The limited ability of many patients to tolerate the intense chemotherapy - based treatments, in particular hematological toxicity, further contributes to the poor outcomes noted in this disease.

It offers to the commercialization of unrelated donor - patient (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders.

The company will supply allogeneic MSCs for the study.